Loading stock data…
LeMaitre Vascular, Inc. (LMAT)
$95.59-1.90 (-1.95%)
Market ClosedLast close Jul 24
LeMaitre Vascular, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LeMaitre Vascular, Inc. in the Healthcare sector is trading at $95.59 with a market capitalization of $2.1B. Wall Street consensus targets $118.75 (8 analysts), implying a +24.2% move over the next 12 months. The stock is currently 19% below its 52-week high of $118.01, remaining 0.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $66.55M↑ | $64.45M↑ | $61.05M↓ | $64.23M↑ | $59.87M |
| Gross Profit | $48.40M↑ | $46.19M↑ | $45.95M↑ | $44.97M↑ | $41.42M |
| Operating Income | $17.77M↓ | $18.83M↓ | $20.31M↑ | $16.14M↑ | $12.63M |
| Net Income | $15.68M↑ | $15.58M↓ | $17.36M↑ | $13.78M↑ | $11.01M |
Peer Comparison
JNJUNHPFE
Fundamentals
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreser...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.68%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.35%
Volume
Today's trading volume
340,832
Recent News
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
1 High-Flying Stock to Target This Week and 2 Facing Headwinds
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
1 Russell 2000 Stock with Exciting Potential and 2 We Find Risky
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
3 of Wall Street’s Favorite Stocks We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
How The LeMaitre Vascular (LMAT) Story Is Shifting As Analysts Lift Fair Value Targets
The fair value price target for LeMaitre Vascular has been updated to US$118.75 from US$111.22, giving you a fresh reference point for what analysts think the stock could be worth on their models. That shift sits alongside a cluster of higher targets from bullish research houses and at least one more neutral call, so you are seeing both enthusiasm and caution reflected in the numbers. Read on to see what is driving this evolving narrative and how you can follow it as new research comes...